Research ArticleArticle
Association of Anticyclic Citrullinated Peptide Antibodies and/or Rheumatoid Factor Status and Clinical Presentation in Early Arthritis: Results from the ESPOIR Cohort
Gaël Mouterde, Cédric Lukas, Philippe Goupille, René-Marc Flipo, Nathalie Rincheval, Jean-Pierre Daurès and Bernard Combe
The Journal of Rheumatology July 2014, jrheum.130884; DOI: https://doi.org/10.3899/jrheum.130884
Gaël Mouterde
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535, Montpellier; Department of Rheumatology, University Hospital of Tours; and UMR CNRS 7292, François Rabelais University, Tours; Rheumatology Department, Roger Salengro Hospital, Lille 2 University, Lille; and Biostatistics, Epidemiology and Clinical Research Unit, IURC, Montpellier and Nîmes, France. Supported by an unrestricted grant from Merck Sharp and Dohme (MSD) for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society for Rheumatology, Abbott, Amgen, and Wyeth-Pfizer also supported the ESPOIR cohort study. G. Mouterde, MD, Rheumatologist; C. Lukas, MD, PhD, Rheumatologist; Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; R.M. Flipo, MD, PhD, Rheumatologist, Rheumatology Department, Roger Salengro Hospital, Lille 2 University; P. Goupille, Rheumatologist, MD, PhD; Department of Rheumatology, University Hospital of Tours; UMR CNRS 7292, François Rabelais University; N. Rincheval, MS2Biostatistics, Biostatistician; J.P. Daurès, MD, PhD, Biostatistician, Biostatistics, Epidemiology and Clinical Research Unit, IURC; B. Combe, MD, PhD, Rheumatologist, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535. Address correspondence to Prof. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 avenue doyen Giraud, 34295 Montpellier, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication April 10, 2014.
Cédric Lukas
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535, Montpellier; Department of Rheumatology, University Hospital of Tours; and UMR CNRS 7292, François Rabelais University, Tours; Rheumatology Department, Roger Salengro Hospital, Lille 2 University, Lille; and Biostatistics, Epidemiology and Clinical Research Unit, IURC, Montpellier and Nîmes, France. Supported by an unrestricted grant from Merck Sharp and Dohme (MSD) for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society for Rheumatology, Abbott, Amgen, and Wyeth-Pfizer also supported the ESPOIR cohort study. G. Mouterde, MD, Rheumatologist; C. Lukas, MD, PhD, Rheumatologist; Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; R.M. Flipo, MD, PhD, Rheumatologist, Rheumatology Department, Roger Salengro Hospital, Lille 2 University; P. Goupille, Rheumatologist, MD, PhD; Department of Rheumatology, University Hospital of Tours; UMR CNRS 7292, François Rabelais University; N. Rincheval, MS2Biostatistics, Biostatistician; J.P. Daurès, MD, PhD, Biostatistician, Biostatistics, Epidemiology and Clinical Research Unit, IURC; B. Combe, MD, PhD, Rheumatologist, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535. Address correspondence to Prof. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 avenue doyen Giraud, 34295 Montpellier, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication April 10, 2014.
Philippe Goupille
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535, Montpellier; Department of Rheumatology, University Hospital of Tours; and UMR CNRS 7292, François Rabelais University, Tours; Rheumatology Department, Roger Salengro Hospital, Lille 2 University, Lille; and Biostatistics, Epidemiology and Clinical Research Unit, IURC, Montpellier and Nîmes, France. Supported by an unrestricted grant from Merck Sharp and Dohme (MSD) for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society for Rheumatology, Abbott, Amgen, and Wyeth-Pfizer also supported the ESPOIR cohort study. G. Mouterde, MD, Rheumatologist; C. Lukas, MD, PhD, Rheumatologist; Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; R.M. Flipo, MD, PhD, Rheumatologist, Rheumatology Department, Roger Salengro Hospital, Lille 2 University; P. Goupille, Rheumatologist, MD, PhD; Department of Rheumatology, University Hospital of Tours; UMR CNRS 7292, François Rabelais University; N. Rincheval, MS2Biostatistics, Biostatistician; J.P. Daurès, MD, PhD, Biostatistician, Biostatistics, Epidemiology and Clinical Research Unit, IURC; B. Combe, MD, PhD, Rheumatologist, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535. Address correspondence to Prof. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 avenue doyen Giraud, 34295 Montpellier, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication April 10, 2014.
René-Marc Flipo
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535, Montpellier; Department of Rheumatology, University Hospital of Tours; and UMR CNRS 7292, François Rabelais University, Tours; Rheumatology Department, Roger Salengro Hospital, Lille 2 University, Lille; and Biostatistics, Epidemiology and Clinical Research Unit, IURC, Montpellier and Nîmes, France. Supported by an unrestricted grant from Merck Sharp and Dohme (MSD) for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society for Rheumatology, Abbott, Amgen, and Wyeth-Pfizer also supported the ESPOIR cohort study. G. Mouterde, MD, Rheumatologist; C. Lukas, MD, PhD, Rheumatologist; Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; R.M. Flipo, MD, PhD, Rheumatologist, Rheumatology Department, Roger Salengro Hospital, Lille 2 University; P. Goupille, Rheumatologist, MD, PhD; Department of Rheumatology, University Hospital of Tours; UMR CNRS 7292, François Rabelais University; N. Rincheval, MS2Biostatistics, Biostatistician; J.P. Daurès, MD, PhD, Biostatistician, Biostatistics, Epidemiology and Clinical Research Unit, IURC; B. Combe, MD, PhD, Rheumatologist, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535. Address correspondence to Prof. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 avenue doyen Giraud, 34295 Montpellier, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication April 10, 2014.
Nathalie Rincheval
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535, Montpellier; Department of Rheumatology, University Hospital of Tours; and UMR CNRS 7292, François Rabelais University, Tours; Rheumatology Department, Roger Salengro Hospital, Lille 2 University, Lille; and Biostatistics, Epidemiology and Clinical Research Unit, IURC, Montpellier and Nîmes, France. Supported by an unrestricted grant from Merck Sharp and Dohme (MSD) for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society for Rheumatology, Abbott, Amgen, and Wyeth-Pfizer also supported the ESPOIR cohort study. G. Mouterde, MD, Rheumatologist; C. Lukas, MD, PhD, Rheumatologist; Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; R.M. Flipo, MD, PhD, Rheumatologist, Rheumatology Department, Roger Salengro Hospital, Lille 2 University; P. Goupille, Rheumatologist, MD, PhD; Department of Rheumatology, University Hospital of Tours; UMR CNRS 7292, François Rabelais University; N. Rincheval, MS2Biostatistics, Biostatistician; J.P. Daurès, MD, PhD, Biostatistician, Biostatistics, Epidemiology and Clinical Research Unit, IURC; B. Combe, MD, PhD, Rheumatologist, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535. Address correspondence to Prof. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 avenue doyen Giraud, 34295 Montpellier, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication April 10, 2014.
Jean-Pierre Daurès
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535, Montpellier; Department of Rheumatology, University Hospital of Tours; and UMR CNRS 7292, François Rabelais University, Tours; Rheumatology Department, Roger Salengro Hospital, Lille 2 University, Lille; and Biostatistics, Epidemiology and Clinical Research Unit, IURC, Montpellier and Nîmes, France. Supported by an unrestricted grant from Merck Sharp and Dohme (MSD) for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society for Rheumatology, Abbott, Amgen, and Wyeth-Pfizer also supported the ESPOIR cohort study. G. Mouterde, MD, Rheumatologist; C. Lukas, MD, PhD, Rheumatologist; Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; R.M. Flipo, MD, PhD, Rheumatologist, Rheumatology Department, Roger Salengro Hospital, Lille 2 University; P. Goupille, Rheumatologist, MD, PhD; Department of Rheumatology, University Hospital of Tours; UMR CNRS 7292, François Rabelais University; N. Rincheval, MS2Biostatistics, Biostatistician; J.P. Daurès, MD, PhD, Biostatistician, Biostatistics, Epidemiology and Clinical Research Unit, IURC; B. Combe, MD, PhD, Rheumatologist, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535. Address correspondence to Prof. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 avenue doyen Giraud, 34295 Montpellier, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication April 10, 2014.
Bernard Combe
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535, Montpellier; Department of Rheumatology, University Hospital of Tours; and UMR CNRS 7292, François Rabelais University, Tours; Rheumatology Department, Roger Salengro Hospital, Lille 2 University, Lille; and Biostatistics, Epidemiology and Clinical Research Unit, IURC, Montpellier and Nîmes, France. Supported by an unrestricted grant from Merck Sharp and Dohme (MSD) for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society for Rheumatology, Abbott, Amgen, and Wyeth-Pfizer also supported the ESPOIR cohort study. G. Mouterde, MD, Rheumatologist; C. Lukas, MD, PhD, Rheumatologist; Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; R.M. Flipo, MD, PhD, Rheumatologist, Rheumatology Department, Roger Salengro Hospital, Lille 2 University; P. Goupille, Rheumatologist, MD, PhD; Department of Rheumatology, University Hospital of Tours; UMR CNRS 7292, François Rabelais University; N. Rincheval, MS2Biostatistics, Biostatistician; J.P. Daurès, MD, PhD, Biostatistician, Biostatistics, Epidemiology and Clinical Research Unit, IURC; B. Combe, MD, PhD, Rheumatologist, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, UMR 5535. Address correspondence to Prof. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 avenue doyen Giraud, 34295 Montpellier, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication April 10, 2014.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Association of Anticyclic Citrullinated Peptide Antibodies and/or Rheumatoid Factor Status and Clinical Presentation in Early Arthritis: Results from the ESPOIR Cohort
Gaël Mouterde, Cédric Lukas, Philippe Goupille, René-Marc Flipo, Nathalie Rincheval, Jean-Pierre Daurès, Bernard Combe
The Journal of Rheumatology Jul 2014, jrheum.130884; DOI: 10.3899/jrheum.130884
Association of Anticyclic Citrullinated Peptide Antibodies and/or Rheumatoid Factor Status and Clinical Presentation in Early Arthritis: Results from the ESPOIR Cohort
Gaël Mouterde, Cédric Lukas, Philippe Goupille, René-Marc Flipo, Nathalie Rincheval, Jean-Pierre Daurès, Bernard Combe
The Journal of Rheumatology Jul 2014, jrheum.130884; DOI: 10.3899/jrheum.130884